To assess the safety and efficacy of the long-term antifibrotic therapy with pirfenidone in patients with idiopathic pulmonary fibrosis in real-life clinical practice.
Material and methods
Disease symptoms, FVC, DLCO) and 6-minute walk test were monitored in 5 patients with IPF who received long-term treatment with pirfenidone.
Long-term follow-up (13-51 months) showed treatment safety and stable course of the disease.
The results of follow-up confirm the safety and efficacy of the long-term antifibrotic therapy with pirfenidone in IPF patients.
Idiopathic pulmonary fibrosis, antifibrotic therapy, pirfenidone.